Abstract: The present disclosure relates to modified homoserine dehydrogenase and a method for producing a homoserine-derived L-amino acid using the same.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
February 1, 2022
Assignee:
CJ CHEILJEDANG CORPORATION
Inventors:
Hyo Jin Kim, Lan Huh, Sang Jo Lim, Hyun Ah Kim, Hyoung Joon Kim, Chang il Seo, Seung Bin Lee, Ji Sun Lee
Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Abstract: Provided is a method for producing a high-density filamentous fungal pellet. A method for producing a filamentous fungal pellet, comprising a step of germinating spores of a filamentous fungus in a culture medium containing a cationic polymer.
Abstract: A recombinant cell and a method of producing itaconic acid using such recombinant cell. The recombinant cell is of the genus Methylorubrum and includes a first polynucleotide sequence as defined in SEQ ID NO: 1 or a homologue thereof operably linked to a regulatory sequence.
Abstract: Provided herein are recombinant glycoproteins (e.g., recombinant human ?-galactosidase-A proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins. Also provided are methods of generating a mammalian cell useful for recombinant expression of a glycoprotein (e.g., recombinant human ?-galactosidase-A), methods of producing recombinant glycoproteins, and methods of treatment that include administering to a subject at least one of the recombinant glycoproteins (e.g., recombinant human ?-galactosidase-A protein).
Type:
Grant
Filed:
October 22, 2014
Date of Patent:
December 28, 2021
Assignee:
GENZYME CORPORATION
Inventors:
Karen Lee, Christopher Hwang, Christine DeMaria
Abstract: The present invention relates to plastic composition comprising at least one polyester, biological entities having a polyester-degrading activity and at least an anti-acid filler, wherein the biological entities represent less than 11% by weight, based on the total weight of the plastic composition, and uses thereof for manufacturing biodegradable plastic articles.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
December 14, 2021
Assignee:
CARBIOS
Inventors:
Elodie Guemard, Michel Chateau, Alain Marty
Abstract: The subject invention relates to a process of preparing (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying with certain carbon and nitrogen sources. These microorganisms include a Glutamic acid Bacterium HR057 strain or one type of genetically engineered Corynebacterium Glutamicum.
Abstract: The present invention relates to a method of increasing biosimilarity of a TNF ? binding protein to a reference TNF ? binding protein by modifying the charge profile of the binding protein produced by cell culture in a cell culture medium, by making an adjustment to a cell culture condition The adjustment is an increase in the concentration of a metal ion in the cell culture medium and the adjustment occurs on one or more days during the cell culture method, whereby the adjustment in the cell culture condition results in the modification of the charge profile of the binding protein. The present invention also relates to a biosimilar protein obtainable by such a process.
Type:
Grant
Filed:
August 6, 2019
Date of Patent:
November 30, 2021
Assignee:
FRESENIUS KABI DEUTSCHLAND GMBH
Inventors:
Thomas Solacroup, Matthieu Stettler, Martin Jordan, Hervé Broly
Abstract: Herein is reported a method for producing an enzymatic conjugation product of three polypeptides comprising the simultaneous incubation of i) a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide comprising the amino acid sequence LPXTA (SEQ ID NO: 31, wherein X can be any amino acid residue), a third polypeptide that has two N-termini whereby the polypeptide has an oligo-glycine Gm (m=2 (SEQ ID NO: 22), or 3 (SEQ ID NO: 23), or 4 (SEQ ID NO: 24), or 5 (SEQ ID NO: 25)) amino acid sequence at its first N-terminus and an oligo-alanine Am (m=2 (SEQ ID NO: 26), or 3 (SEQ ID NO: 27), or 4 (SEQ ID NO: 28), or 5 (SEQ ID NO: 29)) amino acid sequence at its second N-terminus, a fourth polypeptide with sortase activity whereby the polypeptide is derived from Staphylococcus aureus sortase A, and a fifth polypeptide with sortase activity whereby the polypeptide is derived from Streptococcus pyogenes sortase A and the recovering of the c
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
November 2, 2021
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Dieter Heindl, Erhard Kopetzki, Georg Tiefenthaler
Abstract: Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
November 2, 2021
Assignee:
THE TRUSTEES OF PRINCETON UNIVERSITY
Inventors:
Tom W. Muir, Miquel Vila-Perello, Zhihua Liu, Neel H. Shah
Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12×.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
October 12, 2021
Assignee:
Precision BioSciences, Inc.
Inventors:
James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
Abstract: Provided are a group of phi29 DNA polymerase mutants having increased thermal stability and use thereof. The phi29 DNA polymerase mutants are proteins obtained by performing point mutation A and/or point mutation B and/or point mutation C on phi29 DNA polymerase, the point mutation A meaning that an amino acid residue M at position 97 of the phi29 DNA polymerase is mutated to other amino acid residue, the point mutation B meaning that an amino acid residue L at position 123 of the phi29 DNA polymerase is mutated into other amino acid residue, and the point mutation C meaning that an amino acid residue E at position 515 of the phi29 DNA polymerase is mutated to other amino acid residue. The stability of the phi29 DNA polymerase mutants is higher than that of a wild-type phi29 DNA polymerase.
Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
Type:
Grant
Filed:
April 7, 2017
Date of Patent:
July 13, 2021
Assignees:
The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Rutgers, the State University of New Jersey, Skolkovo Institute of Science and Technology, The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Konstantin Severinov, Feng Zhang, Yuri I. Wolf, Sergey Shmakov, Ekaterina Semenova, Leonid Minakhin, Kira S. Makarova, Eugene Koonin, Silvana Konermann, Julia Joung, Jonathan S. Gootenberg, Omar O. Abudayyeh, Eric S. Lander
Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
Abstract: The invention relates to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific manner. The polypeptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.
Abstract: Described herein are recombinant yeast cells expressing a xylulose kinase (XK) which are suitable for fermentation of pentoses. Also described are recombinant yeast cells with higher tolerance to formic and/or acetic acid and suitable for fermentation of pentoses. Also described are recombinant yeast cells expressing an enolase, a phosphofructokinase beta subunit, a 6-phosphofructo-2-kinase, a glucose-6-phosphate isomerase, a phosphoglycerate mutase and/or a triose-phosphate isomerase, and suitable for fermentation of pentoses. Also described are recombinant yeast cells expressing a phosphoglucomutase and/or phosphoribomutase which are suitable for fermentation of pentoses. Further described are methods of using or producing such recombinant yeast cells and related materials.
Type:
Grant
Filed:
December 19, 2017
Date of Patent:
June 29, 2021
Assignee:
Novozymes A/S
Inventors:
Kaisa Karhumaa, Malin Sendelius, Violeta Sánchez I Nógue
Abstract: The present invention relates to the field of fungal production fatty alcohols. More specifically, the present invention relates to genetically modified host cells, nucleic acid constructs and culture medium for the production of fatty alcohols in Rhodosporidium.
Type:
Grant
Filed:
January 29, 2018
Date of Patent:
June 15, 2021
Assignee:
TEMASEK LIFE SCIENCES LABORATORY LIMITED
Inventors:
Lianghui Ji, Yanbin Liu, Chong Mei John Koh, Sihui Amy Yap, Si Te Ngoh